Related Experiment Videos
Advances in the biology of multiple myeloma: therapeutic applications
1Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Recent advances in the biology of multiple myeloma cell growth and survival have suggested new avenues for treatment and potential cure of this disease. Adhesion molecules on the myeloma cell surface mediate their localization in the bone marrow via binding to extracellular matrix proteins and stromal cells. Stromal cell to tumor cell contact and the secretion of transforming growth factor by tumor cells triggers interleukin-6 secretion from stromal cells and paracrine tumor cell growth. CD40 activation of myeloma cells changes their cell surface phenotype, triggers autocrine interleukin-6 secretion, and can regulate myeloma cell cycle in a p53-dependent fashion. Interleukin-6 is both a growth and survival factor for myeloma cells, and delineation of the signaling cascades mediating its effects permits the development of novel therapies either to interrupt growth or trigger apoptosis. New immune therapies offer the opportunity to treat minimal residual disease after stem cell transplantation, thereby improving outcome. Selected donor lymphocyte infusions after allografting and infusion of activated autologous T cells following autografting are examples of adoptive immunotherapy. Myeloma cell to dendritic cell fusions have been used in a vaccination strategy both to prevent and treat myeloma in an animal model, providing the rationale for similar clinical trials in humans. For the first time, a variety of novel treatment strategies derived from advances in understanding the disease pathogenesis offer the potential to achieve long-term disease-free survival in patients with multiple myeloma.
Insights
Advances in understanding multiple myeloma biology reveal new treatment strategies. Novel therapies targeting cell growth and survival offer potential cures and long-term disease-free survival for patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Multiple myeloma cell adhesion molecules mediate bone marrow localization.
- Tumor cell interactions with stromal cells promote interleukin-6 secretion and growth.
- Interleukin-6 acts as a critical growth and survival factor for myeloma cells.
Purpose of the Study:
- To explore novel treatment strategies for multiple myeloma based on recent biological insights.
- To identify therapeutic targets within the interleukin-6 signaling pathway.
- To evaluate the potential of immune-based therapies for managing minimal residual disease.
Main Methods:
- Analysis of myeloma cell adhesion and interaction with bone marrow microenvironment.
- Investigation of CD40 activation effects on myeloma cell phenotype and cell cycle.
- Review of emerging immunotherapies including adoptive T-cell transfer and vaccination strategies.
Main Results:
- Interleukin-6 signaling cascades identified as key targets for therapeutic intervention.
- CD40 activation influences myeloma cell cycle in a p53-dependent manner.
- Novel immune therapies show promise for treating minimal residual disease and preventing relapse.
Conclusions:
- Understanding myeloma pathogenesis has led to promising novel treatment strategies.
- Targeting interleukin-6 signaling and employing immune-based therapies offer potential for cure.
- These advances provide hope for achieving long-term disease-free survival in multiple myeloma patients.